STOCK TITAN

[Form 4] Neuropace, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Joel Becker, Chief Executive Officer and director of NeuroPace Inc. (NPCE), reported a non-discretionary share disposal on 08/27/2025. The filing shows 1,126 shares were withheld by the issuer at an effective price of $8.88 to satisfy tax withholding tied to the vesting of a restricted stock unit award. After this withholding, Becker beneficially owns 104,212 shares, held directly. The form was signed by an attorney-in-fact on 08/28/2025 and records the transaction as a routine tax-withholding disposition related to equity compensation.

Joel Becker, Amministratore Delegato e membro del consiglio di NeuroPace Inc. (NPCE), ha dichiarato una cessione obbligatoria di azioni il 27/08/2025. La documentazione indica che 1.126 azioni sono state trattenute dall'emittente a un prezzo effettivo di $8,88 per soddisfare le ritenute fiscali relative al consolidamento di un premio in unità di azioni vincolate. Dopo questa trattenuta, Becker possiede di fatto 104.212 azioni, detenute direttamente. Il modulo è stato firmato da un procuratore il 28/08/2025 e registra la transazione come una consueta disposizione per trattenuta fiscale connessa alla remunerazione in azioni.

Joel Becker, Director Ejecutivo y miembro del consejo de NeuroPace Inc. (NPCE), reportó una disposición no discrecional de acciones el 27/08/2025. El formulario muestra que 1.126 acciones fueron retenidas por el emisor a un precio efectivo de $8,88 para cubrir la retención fiscal vinculada al otorgamiento de una unidad de acciones restringidas. Tras esta retención, Becker posee de forma beneficiaria 104.212 acciones, en propiedad directa. El documento fue firmado por un apoderado el 28/08/2025 y registra la operación como una disposición rutinaria por retención fiscal relacionada con la compensación en acciones.

조엘 베커, NeuroPace Inc.(NPCE)의 최고경영자 겸 이사가 2025-08-27에 비재량적(의무적) 주식 처분을 신고했습니다. 신고서에 따르면 1,126주가 제한주 단위(RSU)의 취득과 관련된 세금 원천징수를 충당하기 위해 발행사가 유효 단가 $8.88로 원천징수되었다고 기재되어 있습니다. 이 원천징수 이후 베커는 104,212주를 직접 보유하여 실질적으로 소유하고 있습니다. 양식은 2025-08-28에 대리인이 서명했으며, 본 거래는 주식 보상과 관련한 세금 원천징수의 일상적 처분으로 기록되어 있습니다.

Joel Becker, directeur général et administrateur de NeuroPace Inc. (NPCE), a déclaré une cession d'actions non discrétionnaire le 27/08/2025. Le document indique que 1 126 actions ont été retenues par l'émetteur à un prix effectif de 8,88 $ pour satisfaire la retenue fiscale liée à la levée d'une attribution d'unités d'actions restreintes. Après cette retenue, Becker détient à titre bénéficiaire 104 212 actions, détenues directement. Le formulaire a été signé par un mandataire le 28/08/2025 et enregistre la transaction comme une disposition de routine pour retenue fiscale liée à la rémunération en actions.

Joel Becker, Chief Executive Officer und Direktor von NeuroPace Inc. (NPCE), meldete am 27.08.2025 eine nicht-discretionäre Aktienveräußerung. Die Einreichung zeigt, dass 1.126 Aktien vom Emittenten zu einem effektiven Preis von $8,88 einbehalten wurden, um die steuerliche Einbehaltung im Zusammenhang mit der Vesting eines Restricted Stock Unit Awards zu erfüllen. Nach dieser Einbehaltung besitzt Becker wirtschaftlich 104.212 Aktien, die direkt gehalten werden. Das Formular wurde am 28.08.2025 von einem Bevollmächtigten unterzeichnet und verzeichnet die Transaktion als routinemäßige steuerliche Einbehaltung im Zusammenhang mit Aktienvergütung.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine tax-withholding share disposal from RSU vesting; immaterial to company financials.

The 1,126-share disposition at $8.88 is a standard administrative action to satisfy tax obligations from vested restricted stock units. The size of the transaction relative to the total outstanding shares is not provided, and the filing shows no sales into the market or transfers beyond withholding. This activity does not indicate change in insider confidence or a broader liquidity event.

TL;DR: Filing reflects compliance with Section 16 reporting and common equity compensation mechanics.

The Form 4 documents the issuer withholding shares to cover taxes upon RSU vesting, a common practice. Reporting by an attorney-in-fact and timely disclosure (transaction 08/27/2025, filing signed 08/28/2025) suggests proper procedural adherence. There are no indications of policy breaches or unusual related-party transactions in the record provided.

Joel Becker, Amministratore Delegato e membro del consiglio di NeuroPace Inc. (NPCE), ha dichiarato una cessione obbligatoria di azioni il 27/08/2025. La documentazione indica che 1.126 azioni sono state trattenute dall'emittente a un prezzo effettivo di $8,88 per soddisfare le ritenute fiscali relative al consolidamento di un premio in unità di azioni vincolate. Dopo questa trattenuta, Becker possiede di fatto 104.212 azioni, detenute direttamente. Il modulo è stato firmato da un procuratore il 28/08/2025 e registra la transazione come una consueta disposizione per trattenuta fiscale connessa alla remunerazione in azioni.

Joel Becker, Director Ejecutivo y miembro del consejo de NeuroPace Inc. (NPCE), reportó una disposición no discrecional de acciones el 27/08/2025. El formulario muestra que 1.126 acciones fueron retenidas por el emisor a un precio efectivo de $8,88 para cubrir la retención fiscal vinculada al otorgamiento de una unidad de acciones restringidas. Tras esta retención, Becker posee de forma beneficiaria 104.212 acciones, en propiedad directa. El documento fue firmado por un apoderado el 28/08/2025 y registra la operación como una disposición rutinaria por retención fiscal relacionada con la compensación en acciones.

조엘 베커, NeuroPace Inc.(NPCE)의 최고경영자 겸 이사가 2025-08-27에 비재량적(의무적) 주식 처분을 신고했습니다. 신고서에 따르면 1,126주가 제한주 단위(RSU)의 취득과 관련된 세금 원천징수를 충당하기 위해 발행사가 유효 단가 $8.88로 원천징수되었다고 기재되어 있습니다. 이 원천징수 이후 베커는 104,212주를 직접 보유하여 실질적으로 소유하고 있습니다. 양식은 2025-08-28에 대리인이 서명했으며, 본 거래는 주식 보상과 관련한 세금 원천징수의 일상적 처분으로 기록되어 있습니다.

Joel Becker, directeur général et administrateur de NeuroPace Inc. (NPCE), a déclaré une cession d'actions non discrétionnaire le 27/08/2025. Le document indique que 1 126 actions ont été retenues par l'émetteur à un prix effectif de 8,88 $ pour satisfaire la retenue fiscale liée à la levée d'une attribution d'unités d'actions restreintes. Après cette retenue, Becker détient à titre bénéficiaire 104 212 actions, détenues directement. Le formulaire a été signé par un mandataire le 28/08/2025 et enregistre la transaction comme une disposition de routine pour retenue fiscale liée à la rémunération en actions.

Joel Becker, Chief Executive Officer und Direktor von NeuroPace Inc. (NPCE), meldete am 27.08.2025 eine nicht-discretionäre Aktienveräußerung. Die Einreichung zeigt, dass 1.126 Aktien vom Emittenten zu einem effektiven Preis von $8,88 einbehalten wurden, um die steuerliche Einbehaltung im Zusammenhang mit der Vesting eines Restricted Stock Unit Awards zu erfüllen. Nach dieser Einbehaltung besitzt Becker wirtschaftlich 104.212 Aktien, die direkt gehalten werden. Das Formular wurde am 28.08.2025 von einem Bevollmächtigten unterzeichnet und verzeichnet die Transaktion als routinemäßige steuerliche Einbehaltung im Zusammenhang mit Aktienvergütung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Becker Joel

(Last) (First) (Middle)
C/O NEUROPACE INC.
455 N. BERNARDO AVENUE

(Street)
MOUNTAIN VIEW CA 94043

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF EXECUTIVE OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/27/2025 F 1,126(1) D $8.88 104,212 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents the number of shares withheld by the Issuer on August 27, 2025 to satisfy tax withholding obligations in connection with the vesting of a restricted stock unit award.
/s/ Leah Akin, Attorney-in-Fact 08/28/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Neuropace Inc

NASDAQ:NPCE

NPCE Rankings

NPCE Latest News

NPCE Latest SEC Filings

NPCE Stock Data

293.76M
25.14M
2.72%
82.15%
3.38%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW